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Pseudomonas aeruginosa strains that produce metallo--lactamases (MBLs) are becoming increasingly
prevalent. We evaluated the epidemiological and microbiological characteristics of monomicrobial blood-
stream infections caused by MBL-producing P. aeruginosa isolates, as well as the clinical outcomes in patients
with these infections.
Since their first description in the early 1990s (14), metallo-
-lactamase (MBL)-producing organisms have been detected
in many parts of the world (1, 8, 15, 18). MBL-producing
Pseudomonas aeruginosa strains have been reported to be im-
portant causes of nosocomial infections (4, 8, 13). While the
prevalence of these strains in hospitals is still unknown, they
have been reported to be associated with clonal spread and
nosocomial outbreaks (4, 8, 18). The appearance of MBL
genes and their spread among bacterial pathogens are matters
of major concern with regard to the future of antimicrobial
chemotherapy (2). It is well known that a poor outcome occurs
when patients with serious infections due to MBL-producing
organisms are treated with antibiotics to which the organism is
completely resistant (8, 15). Data extrapolated from in vitro
studies suggest that polymyxin B or colistin represents the best
treatment options (10).
Carbapenems are considered indicator drugs for the detec-
tion of resistance mechanisms in Pseudomonas aeruginosa in-
fections (11). Due to the high prevalence of imipenem resis-
tance noted among P. aeruginosa isolates causing bloodstream
infections (BSIs) at our hospital, we decided to investigate
whether MBL production was directly associated with this re-
sistance mechanism and to analyze the epidemiology of these
infections.
This study was carried out at the Universidade Federal de
Sa˜o Paulo, a 624-bed university hospital located in the state of
Sa˜o Paulo, Brazil. All patients for whom blood culture results
were positive for P. aeruginosa from January 2000 to May 2002
were eligible for inclusion in the study. Each patient was in-
cluded only once at the time of the first BSI. Polymicrobial
BSIs and BSI episodes that represented relapses were ex-
cluded. Mortality related to bacteremia was considered present
when a patient died within 14 days of the start of treatment and
the death could not be directly attributed to any other cause.
Data for patients with BSIs due to a MBL genotype-produc-
ing P. aeruginosa isolate were collected by reviews of the pa-
tient’s medical charts and the laboratory database. The data
abstracted included age, sex, the number of hospital days prior
to infection, the length of the hospital stay, the underlying
disease, and antibiotics prescribed for at least 48 h in the 15
days prior to the onset of the BSI (17). The severity of illness
was classified by using the Simplified Acute Physiology Score
(SAPS) (9). The sources of infection were defined according to
Centers for Disease Control and Prevention criteria (7). For
the treatment of MBL-producing Pseudomonas BSIs, only
polymyxin B or colistin was classified as adequate antimicrobial
therapy.
Blood cultures were processed by using the BACTEC 9240
blood culture system (Becton Dickinson, Sparks, MD). Organ-
isms were identified according to routine bacteriological pro-
cedures. Susceptibility testing was performed by the disk dif-
fusion method, following the recommendations of the CLSI
(formerly the National Committee for Clinical Laboratory
Standards) (13). MIC determinations were performed for all
blood isolates by broth microdilution techniques (13). Isolates
were considered susceptible to colistin if the MIC was 2
g/ml (6). P. aeruginosa isolates were also screened for the
presence of the MBL phenotype by using EDTA and 2-mer-
captopropionic acid (2-MPA) for MBL inhibition (1). In ad-
dition, the carbapenemase activities of cell sonicates from
overnight broth cultures were determined by spectrophotomet-
ric assays (3). All strains of P. aeruginosa were tested by PCR
analysis to confirm the presence of the blaIMP, blaVIM, and
blaSPM genes (5, 15, 18). The primers yielded PCR products,
and both strands were sequenced on a Perkin-Elmer system
377 DNA sequencer (12).
During the study, 96 patients with P. aeruginosa BSIs were
identified, of whom 76 had monomicrobial infections. The
MBL phenotype was detected in P. aeruginosa isolates from 23
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of the 76 patients (30.3%) by using EDTA. The production of
MBL was detected in only 6 of these 23 strains by using
2-MPA. Carbapenem hydrolysis was detected in 30.4% (7 of
23) of the EDTA-positive isolates and in all 4 isolates positive
by the 2-MPA test.
Of the 76 P. aeruginosa isolates included in this study, MBL
gene blaSPM-1 was the most prevalent, being recovered from
four (5.3%) of the P. aeruginosa BSI strains, followed by the
blaIMP-1 gene (two strains [2.6%]) and the blaIMP-16 gene (one
strain [1.3%]). No blaVIM MBL gene was detected. Details of
antimicrobial susceptibility testing are shown in Table 1.
Among the P. aeruginosa isolates causing polymicrobial BSIs
that were excluded from the analysis (20.8%), only one MBL
gene (blaSPM-1) was identified. The strain producing that MBL
was detected by both phenotypic methods (EDTA and
2-MPA) and carbapenem hydrolysis.
The clinical characteristics and outcomes of the seven MBL
genotype-producing P. aeruginosa patients are presented in
Table 2. The mean age was 63  13 years (age range, 46 to 80
years). Fifty-seven percent of these patients were male. The
most frequent diagnoses responsible for hospitalization were
solid and hematologic malignancies (42.9%) and gastrointes-
tinal diseases (28.6%). The most frequent sources of BSIs were
gastrointestinal (42.9%). Most BSIs (57.1%) occurred before
21 days of hospitalization. The mean duration of hospitaliza-
tion was 43.8  37.4 days (range, 13 to 117 days). Among these
patients, 85.7% were receiving antimicrobial therapy before
the BSI. Before the BSI, cephalosporins (42.9%) were the most
prescribed antibiotic. Seventy-one percent of the patients infected
with an MBL-producing isolate (71.4%) received inadequate em-
pirical therapy. The majority (71.4%) of the patients infected with
an MBL-producing isolate had a SAPS score 40. Mortality
within 14 days after the BSI occurred in 71.4% of the patients
infected with an MBL-producing isolate. The crude (overall, in-
hospital) mortality of MBL patients was 85.7%.
In conclusion, the overall rates of morbidity and mortality
among patients infected with MBL-producing P. aeruginosa
BSI is high. Notably, in our study, 81.1% of the strains were
resistant to imipenem without MBL production. This demon-
strates that other resistance mechanisms are involved, such as
permeability mutations via the loss of porins or the up-regu-
lation of efflux systems (10, 16). In addition, it is necessary to
identify MBL-producing P. aeruginosa isolates in BSIs so that
appropriate treatment will be provided and to better under-
stand the microbiological characteristics and epidemiology of
MBL-producing strains in other institutions with a high prev-
alence of imipenem-resistant P. aeruginosa strains.
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TABLE 1. Correlation between the MBL genotypes and antimicrobial susceptibility profiles
Genotype
Antimicrobial MIC (g/ml) (susceptibilitya)
Gentamicin Amikacin Ciprofloxacin Aztreonam Cefepime Imipenem Colistin
blaIMP-16 16 (R) 16 (R) 4 (R) 32 (R) 32 (R) 16 (R) 0.5 (S)
blaIMP-1 2 (S) 8 (S) 4 (R) 16 (R) 8 (R) 16 (R) 0.5 (S)
blaIMP-1 2 (S) 8 (S) 4 (R) 16 (R) 16 (R) 16 (R) 0.5 (S)
blaSPM-1 16 (R) 64 (R) 4 (R) 8 (S) 32 (R) 32 (R) 1 (S)
blaSPM-1 16 (R) 64 (R) 4 (R) 8 (S) 32 (R) 32 (R) 1 (S)
blaSPM-1 16 (R) 64 (R) 4 (R) 32 (R) 32 (R) 32 (R) 0.5 (S)
blaSPM-1 16 (R) 64 (R) 4 (R) 16 (R) 32 (R) 32 (R) 1 (S)
a R, resistant; S, susceptible.
TABLE 2. Characteristics of the seven patients with MBL genotype-producing P. aeruginosa isolates
Patient
no.
Age
(yr) Sex
a Diagnosis Site of infection
Hospital
stay
prior to
BSI
(days)
Hospital
stay
(days)
SAPS
score
Previous antibiotic
treatment
Response to
antibiotic
therapy
DNA
sequencing
result
Outcome
1 46 M Gastrointestinal
disease
Gastrointestinal 8 28 30 Quinolone Inadequate IMP-16 Death (related
to BSI)
2 63 F Hematologic
malignancy
Catheter 20 32 31 None Inadequate IMP-1 Death (related
to BSI)
3 61 F Neurologic
disease
Respiratory 41 117 32 Carbapenem Adequate IMP-1 Survival
4 71 M Hematologic
malignancy
Respiratory 22 22 56 Cephalosporin Inadequate SPM-1 Death (related
to BSI)
5 74 M Renal failure Catheter 33 72 44 Carbapenem Adequate SPM-1 Death (not
related to
BSI)
6 80 M Gastrointestinal
disease
Gastrointestinal 0 13 37 Cephalosporin Inadequate SPM-1 Death (related
to BSI)
7 49 F Hematologic
malignancy
Gastrointestinal 21 23 24 Cephalosporin Inadequate SPM-1 Death (related
to BSI)
a M, male; F, female.
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